Nvidia's leadership saga unfolds as demand is surging for Anthropic's IPO

By Mark DeCambre

Three takeaways from Colette Kress's first earnings call as Nvidia's interim CEO. Plus, what Medicare Part B will cost in 2027 and why one investor is eyeing Florida real estate as a stock-market alternative.

Here's what I'm watching this morning: Nvidia. The soap opera.

Who'd have thought a chip maker could generate enough drama to rival HBO's "Succession"?

Five days after stepping down as CEO, Jensen Huang let it be known that he'd be honored to have his job back. He picked the morning of Colette Kress's first earnings call as interim CEO to say so.

Huang said employees, investors and customers had urged him to return. The board? Not so much.

Chairman Harvey Jones opened the call by saying the board had unanimously accepted Huang's resignation and "does not intend to reinstate Jensen as CEO."

Then Kress got the floor. Three things stood out to me:

-- Forecast: Nvidia expects $130 billion in sales in the January quarter. Wall Street had been looking for $125 billion.

-- Collections: Nvidia waited an average of 64 days, up from 60 days. Shipment timing explains part of that. But the company also extended payment terms on some large deals.

-- Retention: Kress acknowledged that employees have "diverse opinions." She said she believes, however, that people are committed to continuing their life's work at Nvidia. Retention will be key.

One detail stuck with me: Nvidia brought Ian Buck, a possible successor to Huang, onto the call for questions. He didn't say a word.

What I'm watching next is how much investors will pay for a piece of Anthropic. The company is expected to price its IPO late Wednesday, and its shares are set to start trading Thursday on the Nasdaq. I'd wish it a drama-free debut, but I don't want to jinx it.

Sign up here to get Need to Know daily.

Three stories worth your time ...

-- What's selling out at Costco? The retailer is benefiting from "apocalyptic concerns."

-- How magnificent are the "Magnificent Seven," really? Only two have managed to beat the S&P 500 since 2025.

-- Gold is in a bear market - and it's hackproof in an increasingly digital world. Is now a good time to buy?

Nvidia's (NVDA) beat-and-raise quarter has appeared to brighten the mood on Wall Street ... for the moment. A number of AI-adjacent investments, from Marvell Technology (MRVL) to Bloom Energy (BE) and GE Vernova (GEV), were trading higher in premarket action.

Investors were also watching the trilateral meeting of President Donald Trump, Russia's Vladimir Putin and China's Xi Jinping at the APEC Summit in China.

Trading strategies:

- Want to earn 5% on shorter-term Treasurys again? Watch for this shift.

-- Check out our live markets coverage.

What Summit still has to prove ...

The FDA wants Summit to run another clinical trial of an experimental lung-cancer drug.

Summit Therapeutics' experimental lung-cancer drug helped delay the disease's progression. Here's why the FDA wants the company (SMMT) to run another trial.

Your 2027 Medicare bill ...

Your standard Medicare Part B premium is going up more than 3% next year. Here's what that means in dollars each month.

Sell stocks and buy Florida?

Nvidia's turmoil has a reader in their late 60s considering Florida real estate. Before moving money out of stocks, they have questions for the Moneyist.

Did shoppers really slow their roll ... ?

U.S. retail sales were up just 0.2% in October. Take cars and gas out of the tally and a wholly different picture of the American consumer starts to emerge. Here's what the data show.

-- MarketWatch Picks: Should your adviser get 1% of your checking account, too?

-- Cascade of outages triggers conspiracy theories - and finger pointing.

-- The seven Anthropic founders who are about to become multibillionaires.

-- AI asked "better questions" than KPMG accountants in pilot audit.

About me

Mark DeCambre is editor in chief of MarketWatch. He has spent more than 20 years covering Wall Street, markets and personal finance, and writes Need to Know, drawing on the award-winning analysis and journalism of the newsroom.

-Mark DeCambre

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

 

(END) Dow Jones Newswires

11-18-26 0723ET

Copyright (c) 2026 Dow Jones & Company, Inc.

The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.

Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.

Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.

Popular

Sponsor Center